Brief: eFFECTOR Receives U.S. FDA Fast Track Designation For Zotatifin In Combination With Fulvestrant And Abemaciclib For Treatment Of Er+/Her2- Advanced Metastatic Breast Cancer
Nov 28 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR
ZOTATIFIN
IN COMBINATION WITH FULVESTRANT AND ABEMACICLIB FOR TREATMENT OF
ER+/HER2- ADVANCED METASTATIC BREAST CANCER
Source text for Eikon: ID:nGNXqFXwL
Further company coverage: EFTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Effector Therapeutics
See all newsBrief: Effector Therapeutics Expects To Incur One-Time Charges And Cash Expenditures
Brief: Effector Therapeutics Announces It Will Wind Down Operations
Brief: Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
eFFECTOR Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: eFFECTOR Therapeutics Enters Into An At The Market Offering Agreement With H.C. Wainwright